Clinical Trials
Work with us to further our vision of improving research translation for better health outcomes for all. We welcome inquiries and engagement from patients, consumers and all health and medical researchers, clinicians and administrators.
Join a Clinical Trial
Each clinical trial has guidelines drawn up that specify which patients are suitable (inclusion criteria) or unsuitable (exclusion criteria) for the particular study. These criteria are based on factors such as age, type of disease, medical history and current medical condition. The purpose is to make sure that the study is suitable for the patients who are enrolled in it and that the risks are minimized.
Clinic trials
To that end, our capacity and capabilities encompass the following:
Cardiology
Use of QCZ484 for Treating Adults With Mild to Moderate High Blood Pressure
Endocrinology/Cardiology
Investigational Weight Loss and HFpEF Treatment Study
Cardiology/Nephrology
Investigational Treatment Study of AZD4144 in Cardiovascular and Chronic Kidney Disease Patients
Endocrinology
Investigational Study to Assess the Safety and Effectiveness of Wegovy® in the Treatment of Obesity
Pulmonology
Phase III Clinical Study Testing Dexpramipexole’s Safety and Efficacy in The Treatment of Eosinophilic Asthma Patients
Endocrinology
Investigational Study of STABLECAMP in the Treatment of Diabetic Foot and Venous Leg Ulcers
Cardiology
Heart Attack and Stroke Prevention Study Comparing Imaging-Based CAD Staging vs Traditional Risk Evaluation
Rheumatology
Phase 3, Randomized, Double-blind, Investigational Treatment Study of AR882 in Gout Patients
Endocrinology
Venous Leg Ulcer Treatment Study Designed to Test Whether a New treatment Can be Effective
Rheumatology
Multi-center Study Evaluating the Safety and Effectiveness of Dapansutrile Tablets in Treating Acute Gout Flares
Cardiology
For Treating Adults With Mild to Moderate High Blood Pressure
Endocrinology/Cardiology
Investigational Weight Loss and Treatment Study
Cardiology/Nephrology
Investigational Treatment Study in Cardiovascular and Chronic Kidney Disease Patients
Endocrinology
Investigational Study to Assess the Safety and Effectiveness in the Treatment of Obesity
Pulmonology
Phase III Clinical Study Testing Dexpramipexole’s Safety and Efficacy in The Treatment of Eosinophilic Asthma Patients
Endocrinology
Investigational Study in the Treatment of Diabetic Foot and Venous Leg Ulcers
Cardiology
Heart Attack and Stroke Prevention Study Comparing Imaging-Based CAD Staging vs Traditional Risk Evaluation
Rheumatology
Phase 3, Randomized, Double-blind, Investigational Treatment Study in Gout Patients
Endocrinology
Venous Leg Ulcer Treatment Study Designed to Test Whether a New treatment Can be Effective
Rheumatology
Multi-center Study Evaluating the Safety and Effectiveness of Dapansutrile Tablets in Treating Acute Gout Flares
Ongoing Trials & Criteria
Use of for Treating Adults With Acute Gout Flare
Site/Study Location
Tarzana
Protocol
OLT1177-08
Trail Details
Gout is a common and painful form of inflammatory arthritis caused by elevated levels of uric acid in the blood, leading to the formation of urate crystals in joints. Acute gout flares can cause sudden and severe pain, redness, and swelling, most commonly in the lower extremities. Current treatments may be insufficient or poorly tolerated by some patients, especially those with comorbidities. This clinical study investigates the safety and efficacy of OLT1177, a selective NLRP3 inflammasome inhibitor, in treating adults experiencing an acute gout flare.
Approximately 250 participants are expected to be enrolled. The primary objective is to evaluate the reduction in pain and inflammation associated with acute gout flares through targeted inhibition of the inflammatory cascade.
Inclusion Criteria
Age and Consent: Adults aged 18–75 who are capable of providing written informed consent.
Diagnosis: Confirmed diagnosis of gout with at least one documented acute flare in the past year.
Current Flare Status: Participants must be experiencing a qualifying acute gout flare at screening or randomization.
Pain Level: Moderate to severe pain in the affected joint, typically rated ≥5 on a numeric pain scale.
Compliance: Participants must be willing and able to comply with study procedures and follow-up schedules.
Exclusion Criteria
Secondary Arthritis: Presence of other inflammatory joint diseases, such as rheumatoid arthritis or psoriatic arthritis.
Infection or Septic Arthritis: Any active infection or suspected joint infection.
Kidney Impairment: Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m².
Hepatic Impairment: Elevated liver enzymes (ALT/AST >3x ULN) or known liver disease.
Recent Experimental Treatment: Use of any investigational drug within 30 days prior to screening.
NSAID or Steroid Contraindication: Known intolerance or medical contraindications to study-permitted anti-inflammatory rescue therapies.
Comorbid Conditions: Any uncontrolled comorbidities that could increase risk or interfere with study outcomes.
Substance Abuse: History of alcohol or drug abuse within the past 12 months.
Pregnancy and Nursing: Women who are pregnant, breastfeeding, or planning pregnancy during the study. Women of childbearing potential must use highly effective contraception.
Male Participants: Men with partners of childbearing potential must use condoms during the study and for a specified period thereafter, in accordance with the protocol.
Benefits of Participation
Participants may receive study-related care and medication at no cost.
Compensation may be provided for time and travel.
No personal health insurance is required to participate.
Care will be provided by board-certified physicians and experienced clinical research staff.
Use of (Troculeucel) for Treating Adults With Moderate Alzheimer’s Disease
Site/Study Location
Tarzana
Protocol
SNK01-AD01
Trail Details
Alzheimer’s disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and functional impairment. Moderate Alzheimer’s is marked by increasing difficulty with daily tasks, language problems, and confusion about time or place. There is a significant need for therapies that can modify the course of the disease or improve cognitive function and quality of life.
This clinical trial investigates SNK01, now referred to as troculeucel, an autologous, enhanced Natural Killer (NK) cell therapy developed by NKGen Biotech, Inc., for its safety and potential efficacy in slowing or reversing disease progression in individuals with moderate Alzheimer’s disease.
Approximately 30 participants are expected to be enrolled in this Phase 2 randomized, double-blind clinical trial, with 20 receiving troculeucel and 10 receiving placebo. The primary objective is to evaluate the reduction in cognitive decline associated with moderate Alzheimer’s disease through targeted NK cell therapy.
Inclusion Criteria
Age and Consent: Adults aged 50–85 who are capable of providing informed consent or have a legally authorized representative who can do so.
Diagnosis: Documented diagnosis of moderate Alzheimer’s disease, typically supported by MMSE (Mini-Mental State Examination) scores between 10–20.
Brain Imaging: MRI or CT scan confirming Alzheimer’s-related neurodegenerative changes.
Stability: Must have been on a stable dose of Alzheimer’s medication (if any) for at least 3 months prior to screening.
Study Partner: Availability of a reliable caregiver or study partner who can assist with compliance and attend visits.
Exclusion Criteria
Other Dementias: Diagnosis of other types of dementia, such as vascular dementia or frontotemporal dementia.
Severe Psychiatric Illness: Major depression, schizophrenia, or any other psychiatric disorder that may confound assessments.
Recent Clinical Trial Participation: Enrollment in another investigational study within the last 30 days.
Uncontrolled Medical Conditions: Including unstable cardiovascular disease, severe renal or hepatic impairment, or active cancer.
Immunosuppressive Therapy: Use of chronic corticosteroids or other immunosuppressants.
Infections: Active systemic infections, including hepatitis B, hepatitis C, or HIV.
Allergy or Hypersensitivity: Known allergies to components of the cell therapy product.
Other Neurodegenerative Disorders: Such as Parkinson’s disease or Huntington’s disease.
Benefits of Participation
Participants may receive novel investigational cell therapy at no cost.
Comprehensive medical oversight by board-certified physicians and trained staff throughout the study.
Regular monitoring of cognitive function, safety labs, and health status.
Compensation may be provided for time and travel.
Participation contributes to advancing research in Alzheimer’s disease therapies.
Register Your Interest Here
Please tell us about yourself. All the information you complete will remain private.
